nach oben

Erschienen in:

01.12.2007 | Original Article

Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions

verfasst von: Mehmet Kanbay, Adem Ozkara, Yusuf Selcoki, Bunyamin Isik, Faruk Turgut, Nuket Bavbek, Ebru Uz, Ali Akcay, Ramazan Yigitoglu, Adrian Covic

Erschienen in: International Urology and Nephrology | Ausgabe 4/2007

Einloggen, um Zugang zu erhalten

Abstract

Background

Hyperuricemia has been associated with the development of hypertension, cardiovascular, and renal disease. However, there is no data about the effect of lowering uric acid level on hypertension, renal function, and proteinuria in patients with glomerular filtration rate (GFR) >60 ml/min. We therefore conducted a prospective study to investigate the benefits of allopurinol treatment in hyperuricemic patients with normal renal function.

Materials and methods

Forty-eight hyperuricemic and 21 normouricemic patients were included in the study. Hyperuricemic patients received 300 mg/day allopurinol for three months. All patients’ serum creatinine level, 24-h urine protein level, glomerular filtration rate, and blood pressure levels were measured at baseline and after three months of treatment.

Results

A total of 59 patients completed the three-month follow-up period of observation. In the allopurinol group, serum uric acid levels, GFR, systolic and diastolic blood pressure, and C-reactive protein (CRP) levels significantly improved (P < 0.05). However, urine protein excretion remained unchanged (P > 0.05). No correlation was observed between changes in GFR and changes in CRP, or blood pressure in the allopurinol group. No significant changes were observed in the control group (P > 0.05).

Conclusion

We bring indirect evidence that hyperuricemia increases blood pressure, and decreases GFR. Hence, management of hyperuricemia may prevent the progression of renal disease, even in patients with normal renal function, suggesting that early treatment with allopurinol should be an important part of the management of chronic kidney disease (CKD) patients. Long-term follow-up studies are warranted to identify the benefits of uric acid management on renal function and hypertension.

Iseki K, Ikemiya Y, Inoue T, Iseki C, Kinjo K, Takishita S (2004) Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis 44(4):642–650PubMedCrossRef

Lehto S, Niskanen L, Ronnemaa T, Laakso M (1998) Serum uric acid is a strong predictor of stroke in patients with non-insulin-dependent diabetes mellitus. Stroke 29(3):635–639PubMed

Brand FN, McGee DL, Kannel WB, Stokes J 3rd, Castelli WP (1985) Hyperuricemia as a risk factor of coronary heart disease: the Framingham Study. Am J Epidemiol 121(1):11–18PubMed

Johnson RJ, Kivlighn SD, Kim YG, Suga S, Fogo AB (1999) Reappraisal of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular disease, and renal disease. Am J Kidney Dis 33(2):225–234PubMed

Kang DH, Nakagawa T, Feng L, Watanabe S, Han L, Mazzali M, Truong L, Harris R, Johnson RJ (2002) A role for uric acid in the progression of renal disease. J Am Soc Nephrol 13(12):2888–2897PubMedCrossRef

Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S, Tuttle KR, Rodriguez-Iturbe B, Herrera-Acosta J, Mazzali M (2003) Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 41(6):1183–1190PubMedCrossRef

Schmidt MI, Duncan BB, Watson RL et al (1996) A metabolic syndrome in whites and African-Americans. The Atherosclerosis Risk in Communities baseline study. Diabetes Care 19:414–418PubMedCrossRef

Yoo TW, Sung KC, Shin HS et al (2005) Relationship between serum uric acid concentration and insulin resistance and metabolic syndrome. Circ J 69:928–933PubMedCrossRef

Vuorinen-Markkola H, Yki-Jarvinen H (1994) Hyperuricemia and insulin resistance, J Clin Endocrinol Metab 78:25–29PubMedCrossRef

10.

Nakagawa T, Hu H, Zharikov S et al (2006) A causal role for uric acid in fructose-induced metabolic syndrome, Am J Physiol Renal Physiol 290:625–631CrossRef

11.

Farquharson CA, Butler R, Hill A et al (2002) Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation 106:221–226PubMedCrossRef

12.

Whelton PK, Perneger TV, He J et al (1996) The role of blood pressure as a risk factor for renal disease: a review of the epidemiologic evidence. J Hum Hypertens 10:683–689PubMed

13.

Tsouli SG, Liberopoulos EN, Mikhailidis DP, Athyros VG, Elisaf MS (2006) Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander? Metabolism 55(10):1293–1301PubMedCrossRef

14.

Levey A, Greene T, Kusek J, Beck G (2000) A simplified equation to predict glomerular filtration rate from serum creatinine (abstract A0828). J Am Soc Nephrol 11:155A

15.

Johnson RJ, Segal MS, Srinivas T, Ejaz A, Mu W, Roncal C, Sanchez-Lozada LG, Gersch M, Rodriguez-Iturbe B, Kang DH, Acosta JH (2005) Essential hypertension, progressive renal disease, and uric acid: a pathogenetic link? J Am Soc Nephrol 16(7):1909–1919PubMedCrossRef

16.

Cannon PJ, Stason WB, Demartini FE, Sommers SC, Laragh JH (1966) Hyperuricemia in primary and renal hypertension. N Engl J Med 275(9):457–464PubMedCrossRef

17.

Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, Lan HY, Kivlighn S, Johnson RJ (2001) Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 38(5):1101–1106PubMedCrossRef

18.

Rao GN, Corson MA, Berk BC (1991) Uric acid stimulates vascular smooth muscle cell proliferation by increasing platelet-derived growth factor A-chain expression. J Biol Chem 266(13):8604–8608PubMed

19.

Harris RC, Breyer MD (2001) Physiological regulation of cyclooxygenase-2 in the kidney. Am J Physiol Renal Physiol 281(1):F1–F11PubMed

20.

Lip GY, Beevers M, Beevers DG (2000) Serum urate is associated with baseline renal dysfunction but not survival or deterioration in renal function in malignant phase hypertension. J Hypertens 18(1):97–101PubMedCrossRef

21.

Iseki K, Oshiro S, Tozawa M, Iseki C, Ikemiya Y, Takishita S (2001) Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects. Hypertens Res 24(6):691–697PubMedCrossRef

22.

23.

Sanchez-Lozada LG, Tapia E, Santamaria J, Avila-Casado C, Soto V, Nepomuceno T, Rodriguez-Iturbe B, Johnson RJ, Herrera-Acosta J (2005) Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int 67(1):237–247PubMedCrossRef

24.

Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J (2006) Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440(7081):237–241PubMedCrossRef

25.

Choi HK, Mount DB, Reginato AM (2005) American College of Physicians; American Physiological Society. Pathogenesis of gout. Ann Intern Med 143(7):499–516PubMed

26.

Shi Y, Evans JE, Rock KL (2003) Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 425(6957):516–521PubMedCrossRef

27.

Rodriguez-Iturbe B, Johnson RJ, Herrera-Acosta J (2005) Tubulointerstitial damage and progression of renal failure. Kidney Int Suppl (99):S82–S86

28.

Rodriguez-Iturbe B, Johnson RJ (2006) Role of inflammatory cells in the kidney in the induction and maintenance of hypertension. Nephrol Dial Transplant 21(2):260–263PubMedCrossRef

29.

Gersch MS, Johnson RJ (2006) Uric acid and the immune response. Nephrol Dial Transplant 21(11):3046–3047PubMedCrossRef

30.

Kanellis J, Watanabe S, Li JH, Kang DH, Li P, Nakagawa T, Wamsley A, Sheikh-Hamad D, Lan HY, Feng L, Johnson RJ (2003) Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension 41(6):1287–1293PubMedCrossRef

31.

Gu L, Okada Y, Clinton SK, Gerard C, Sukhova GK, Libby P, Rollins BJ (1998) Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell 2(2):275–281PubMedCrossRef

32.

33.

Nakagawa T, Mazzali M, Kang DH, Kanellis J, Watanabe S, Sanchez-Lozada LG, Rodriguez-Iturbe B, Herrera-Acosta J, Johnson RJ (2003) Hyperuricemia causes glomerular hypertrophy in the rat. Am J Nephrol 23(1):2–7PubMedCrossRef

34.

Siu YP, Leung KT, Tong MK, Kwan TH (2006) Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 47(1):51–59PubMedCrossRef

35.

Khosla UM, Zharikov S, Finch JL, Nakagawa T, Roncal C, Mu W, Krotova K, Block ER, Prabhakar S, Johnson RJ (2005) Hyperuricemia induces endothelial dysfunction. Kidney Int 67(5):1739–1742PubMedCrossRef

36.

Butler R, Morris AD, Belch JJ, Hill A, Struthers AD (2000) Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. Hypertension 35(3):746–751PubMed

Titel: Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions
verfasst von: Mehmet Kanbay
Adem Ozkara
Yusuf Selcoki
Bunyamin Isik
Faruk Turgut
Nuket Bavbek
Ebru Uz
Ali Akcay
Ramazan Yigitoglu
Adrian Covic
Publikationsdatum: 01.12.2007
Verlag: Springer Netherlands
Erschienen in: International Urology and Nephrology / Ausgabe 4/2007
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI: https://doi.org/10.1007/s11255-007-9253-3

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions